Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Large prospective study to evaluate a non-invasive prenatal screening test

Published on Feb. 8, 2026

Got story updates? Submit your updates here. ›

Natera, Inc., a global leader in cell-free DNA and precision medicine, has announced the launch of EDEN, a large, multi-center prospective study designed to evaluate the company's non-invasive prenatal screening test for early risk assessment of preeclampsia and other serious pregnancy complications.

Why it matters

Preeclampsia affects approximately 5-8% of pregnancies and remains a leading cause of maternal and neonatal morbidity. Current risk assessment relies primarily on clinical characteristics and does not provide individualized estimates of risk or response to preventive strategies. The EDEN study aims to evaluate Natera's integrated prenatal risk assessment test, which combines cell-free DNA, additional analytes, and clinical data to identify risk for preeclampsia and other adverse pregnancy outcomes.

The details

EDEN is designed as a definitive prospective study of Natera's integrated prenatal risk assessment test. The study plans to enroll up to 7,500 pregnant participants in the United States between 9 and 15 weeks' gestation to evaluate risk for preeclampsia, including earlier-onset and more severe disease, along with additional adverse pregnancy outcomes. Natera's new test builds on previously published research demonstrating associations between cell-free DNA characteristics and adverse pregnancy outcomes.

  • The EDEN study is launching in 2026.

The players

Natera, Inc.

A global leader in cell-free DNA and precision medicine, dedicated to oncology, women's health, and organ health.

Sheetal Parmar

Senior vice president of medical affairs at Natera.

Got photos? Submit your photos here. ›

What they’re saying

“For more than a decade, Natera has advanced pregnancy care through highly sensitive, non-invasive testing. With EDEN, we are evaluating a next-generation test designed to identify pregnancies at increased risk for preeclampsia and other serious complications earlier and with greater precision, using data that are already part of routine prenatal care.”

— Sheetal Parmar, Senior vice president of medical affairs at Natera (Business Wire)

What’s next

The EDEN study plans to enroll up to 7,500 pregnant participants in the United States between 9 and 15 weeks' gestation to evaluate the performance of Natera's integrated prenatal risk assessment test.

The takeaway

Natera's EDEN study aims to develop a more comprehensive and accurate approach to assessing the risk of preeclampsia and other serious pregnancy complications, which could lead to earlier interventions and improved maternal and fetal outcomes.